Bayer has revealed results from the QUANTI Pediatric study, adding to the safety and efficacy data of the investigational low-dose MRI gadolinium-based contrast agent (GBCA) gadoquatrane.
Redefining prostate cancer diagnosis and care Bayer has outlined an ambitious new vision for transforming prostate cancer care globally, emphasizing innovation in imaging, early detection, and patient-centered treatment strategies. Presented ahead of the European Society for Medical Oncology (ESMO) 2025 Congress, the initiative reflects Bayer’s commitment to redefining standards in oncology and radiology through scientific […]
Bayer has submitted a groundbreaking marketing authorisation application to Japan’s Ministry of Health, Labour, and Welfare for gadoquatrane, an investigational contrast agent that could significantly improve MRI safety protocols. The macrocyclic agent delivers a remarkable 60% reduction in gadolinium exposure compared to standard-of-care agents, addressing critical concerns about cumulative gadolinium retention in patients requiring multiple […]
April 2024
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@interhospi.com
PanGlobal Media IS not responsible for any error or omission that might occur in the electronic display of product or company data.